-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Freiburg, Germany, October 12, 2021/PRNewswire/ - The outstanding biologics manufacturer Eleva is advancing its drug candidates (such as immunomodulatory factor H) into the clinical phase and is cooperating with many pharmaceutical partners
.
Eleva's moss-based platform is ideal for producing drug candidates that are difficult to express but have therapeutic prospects
Eleva recently expanded its production capacity in order to implement clinical studies of drug candidates
.
The earliest of these is Factor H, which will be developed in Phase II
Eleva's moss-based platform provides unique advantages for recombinant protein development.
Such as:
The bryoose structure inherently lacks core α-1,6 fucose (a known allergen), and any other glycan can be "humanized"
.
This will result in good organ uptake
Eleva is using these advantages to produce complex proteins for future treatments (such as second-generation tumor therapy drugs), or virus-like particles (VLP) for vaccine development
.
Ralf Smit, Chief Brand Officer of Eleva, said: "With the continuous expansion of production scale, we are currently able to cooperate with many partners in the pharmaceutical industry to develop therapeutic proteins that are difficult to express
.
We look forward to our moss platform being able to release complex drug candidates.
About Eleva
Headquartered in Freiburg, Germany, Eleva is committed to co-developing new biological therapies with pharmaceutical partners
.
This private company uses its unique moss-based production platform to produce top biological agents such as antibodies, replacement enzymes or fusion toxins
